Eli Lilly

5 Key Things to Watch In the Stock Market This Week

Among the events that will move the stock market this week -- big changes for a smartphone pioneer in trouble, and a big debut for a video streaming service trying to keep its momentum. Here's your quick guide to the days ahead on Wall Street.

What Will $1 Million Get You in Retirement?

Many people believe that $1 million is a comfortable amount to meet their retirement goals. We can also look at the different ways in which a couple can use this $1 million without running out of money.

A Word From Bernanke Turns Stocks Around

Stocks opened lower Friday but reversed course after a letter surfaced from Federal Reserve Chairman Ben Bernanke, suggesting there was room for the central bank to do more to help the economy.

Stocks Dip After Disappointing Manufacturing Data

The Commerce Department says orders for long-lasting factory goods, such as computers and industrial machinery, fell in July. That excluded gains from the transportation category, which is volatile and rose largely because of orders at Boeing.

Many Fortune 500 Firms Pay Less in Income Taxes Than You

It's widely known that millionaires and billionaires pay taxes at a lower rate than those of us who make much less. But did you know that Americans collectively pay far higher income tax rates than many U.S. companies with billions of dollars in profits?

Is Your Doctor on Big Pharma's Payroll?

Drug companies spend hundreds of millions of dollars a year to influence doctors' prescribing habits -- money that often goes directly into physicians' pockets for "consulting fees" and "educational presentations." Wondering if your doc one of them? The nonprofit journalists at ProPublica can tell you.

Big Pharma Ads Flaunt FDA Rules

Officially, it's the FDA's job to ensure that pharmaceutical ads adhere to guidelines. But the agency's annual compliance budget is $9 million, while drug companies spend $58 billion a year on marketing. So it comes as no surprise that only 18% of ads are in compliance with the rules. But it's still disturbing: This is your health.

The Dark Cloud Over Growing Antidepressant Prescriptions

They call it the Great "Recession," but there's no question that these are depressing times. And doctors are writing scripts for antidepressants at an alarming rate -- especially given that many of these doctors aren't psychiatrists. What are the effects on patients who haven't been properly screened?

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Two Reasons for Clinical Data Shares to Soar Again

From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver. As the number of people with diabetes and prediabetes explodes, drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

Merck KGaA Is Latest Pharma to Settle Justice Department Claims

German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.

AstraZeneca's Heart Drug Brilinta: The FDA Is Ready to Rule

More than a year after AstraZeneca filed for approval of its heart drug Brilinta, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.

Can GE and J&J Help Detect Alzheimer's Earlier?

Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.

A New Antidepressant Maker Has Lots of Folks Excited

Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK'd, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are said to looking to buy the startup.